First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, FIH study designed to evaluate the safety, tolerability, PK,
pharmacodynamics, and preliminary antineoplastic activity of RLY-4008, a potent and highly
selective fibroblast growth factor receptor 2 (FGFR2) inhibitor administered orally patients
with unresectable or metastatic ICC and other unresectable or metastatic solid tumors. This
study consists of 2 parts, a dose escalation (Part 1) and a dose expansion (Part 2).